Endocrine Testing Market Snapshot
|Study Period:||2018 - 2026|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The endocrine testing market was valued at USD 9,170.62 million in 2020, and it is expected to reach USD 13,119.51 million by 2026, registering a CAGR of 6.15% during the forecast period.
During the pandemic, many research studies have been demonstrated that people with thyroid disorders are more prone to the COVID 19 infection, creating a significant demand for various endocrine tests globally to check and manage the thyroid hormone levels. As per the January 2021 research study titled “Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study”, the more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance. The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. Hence, the changes in serum TSH and TT3 levels are the important manifestations of the courses of COVID-19.
The growing prevalence of endocrine disorders and advancements in diagnostic technologies are primarily driving the market growth. Furthermore, the growing older population, coupled with rising awareness about early diagnosis and treatment around the world, is anticipated to boost the market growth. Endocrine testing refers to the measuring of levels of hormones secreted by the endocrine glands and the diagnosis of various disorders such as obesity, diabetes, and thyroid disease. According to the International Federation, in 2019, approximately 463 million adults were living with diabetes, and by 2045, this number will rise to 700 million.
According to the World Health Organization, the prevalence of obesity tripled in 2016 compared to the levels in 1975. About 1.9 billion adults aged 18 years or above were overweight. Of these, about 650 million were obese. These numbers roughly translate to 39% and 13% of the adults as overweight and obese, respectively. About 38 million children under the age of five were overweight or obese in 2019. In addition, alcohol consumption is one of the largest risk factors for various endocrine diseases and disabilities. Globally, high-income countries of the developed region have the highest alcohol consumption. This high consumption of alcohol is also serving as one of the major factors for the burden of the disease. Due to the demand for endocrine testing tools, market players are also focusing on product development and novel launches. For instance, in October 2018, DRG Diagnostics launched Free T4 ELISA test kits. The Free T4 ELISA Assay Kit is intended for the direct quantitative determination of free thyroxine in human serum.
The growing prevalence of diabetes, thyroid disorders in many of the countries around the world are anticipated to further fuel the market growth. However, the high cost for the development of testing technologies is expected to impede market growth over the forecast period.
Scope of the Report
As per the scope, endocrine testing refers to devices that are used in the measurement of the level of hormones produced by the endocrine glands in the human body. Endocrine testing helps physicians to determine if any endocrine disorders and further treatment of the condition or diseases. The endocrine testing market is segmented by test ((thyroid test, insulin test, human chorionic gonadotropin test, prolactin test, luteinizing hormone test, progesterone test, and others), technology (immunoassay, tandem mass spectroscopy, sensor technology, and others), end-user (hospitals, clinical laboratories, and others), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.
|Human Chorionic Gonadotropin Test|
|Luteinizing Hormone Test|
|Tandem Mass Spectroscopy|
|By End User|
|Other End Users|
Key Market Trends
Thyroid Stimulating Hormone Testing (TSH) Anticipated to have Lucrative Growth
Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and stimulates the thyroid gland to produce thyroxine and triiodothyronine, which helps in metabolism. TSH testing is used to measure thyroid levels. The burden of thyroid disorders is increasing across the globe. For instance, as per the American Thyroid Association (ATA), an estimated 20 million Americans had some form of thyroid disease in 2019. More than 12% of the US population is anticipated to develop a thyroid condition during their lifetime. The major risk factors for thyroid-associated disorders are smoking, alcohol, and tobacco consumption. As per November 2019 study conducted by researchers from the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, the results of the study demonstrated that Cigarette smoking is associated with a moderately higher level of FT4 and FT3, and lower TSH levels, which suggest partly opposing effects of alcohol consumption.
TSH measurement has recently gained importance in thyroid function testing mainly due to the technological developments in these tests facilitating cost-effective disease screening. TSH also introduced new definitions of subclinical hypothyroidism or hyperthyroidism, along with delivering biochemical treatment targets. Furthermore, advancements in product technologies, coupled with the growing affordability for healthcare, are fueling the market growth. Mass spectroscopy is now used along with liquid chromatography for accurate results, which will fuel the market growth over the forecast period.
To understand key trends, Download Sample Report
North America is Anticipated to have Significant Share
North America is anticipated to have a significant share, owing to the factors such as well-established healthcare infrastructure, high prevalence of obesity, advancements in diagnostic technologies, and new product launches. The less physical activity and growing prevalence of thyroid disorders are anticipated to fuel the market growth.
According to Health and Human Services (HHS), only less than 5% of adults participate in 30 minutes of physical activity each day in the United States. More than 80% of adults do not meet the required guidelines for muscle strengthening and aerobic activities, which is leading to the consequences such as an imbalance of hormones due to obesity and diseases or conditions associated with the thyroid, augmenting the demand for thyroid testing services. According to the American Cancer Society, about 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) and about 2,200 deaths from thyroid cancer (1,050 men and 1,150 women) will be reported in the United States in 2021.
North America is likely to witness major growth in the coming years, owing to several initiatives, such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research work on thyroid hormone function, cost-effective methods to detect thyroid cancer, promising research on Graves’ disease, which is likely to further lead to improved prognosis, and new preventive treatments of thyroid diseases.
In Mexico, the growth is attributed to the rising prevalence of the disorders, coupled with innovative product launches. For instance, in 2018, MedTech pioneer Proteomics International Laboratories Ltd launched its world-leading predictive diagnostic test for diabetic kidney disease, "PromarkerD, “ in Mexican market. Hence, owing to the above-mentioned factors, the market studied is expected to grow over the forecast period in the region.
To understand geography trends, Download Sample Report
The global endocrine testing market is moderately competitive, and there are several local and international companies in this market. Market players are focusing on new product launches, product innovations, and geographical expansions. The key market players operating in the market include Bio-Rad Laboratories Inc., Agilent Technologies Inc., bioMérieux SA, F. Hoffmann-La Roche Ltd, and Siemens AG.
In July 2020, Renalytix AI and Mount Sinai Health System collaborated to study COVID-19 patients and their risk of acute and chronic kidney disease. The study, Prediction of Major Adverse Kidney Events and Recovery (Pred-MAKER), will use the KidneyIntelX to analyze plasma and urine biomarkers in admitted patients.
In January 2020, SphingoTec GmbH launched its IB10 sphingotest penKid, a CE-IVD-marked point-of-care test for Proenkephalin (penKid), a biomarker that allows real-time assessment of kidney function with a simple blood test.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Endocrine Disorders and Increasing Geriatric Population
4.2.2 Advancements in Product Technologies
4.3 Market Restraints
4.3.1 High Cost of Advanced Endocrine Testing Devices
4.3.2 Lack of Awareness in Underdeveloped and Developing Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test
5.1.1 Thyroid Test
5.1.2 Insulin Test
5.1.3 Human Chorionic Gonadotropin Test
5.1.4 Prolactin Test
5.1.5 Luteinizing Hormone Test
5.1.6 Progesterone Test
5.1.7 Other Tests
5.2 By Technology
5.2.2 Tandem Mass Spectroscopy
5.2.3 Sensor Technology
5.2.4 Other Technologies
5.3 By End User
5.3.2 Clincal Laboratories
5.3.3 Other End Users
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 AB Sciex
6.1.2 Abbott Laboratories
6.1.3 Agilent Technologies Inc.
6.1.4 Biomedical Technologies
6.1.5 bioMerieux SA
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 Danaher Corporation
6.1.8 DiaSorin SpA
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 Hologic Inc.
6.1.11 Ortho Clinical Diagnostics
6.1.12 Qiagen NV
6.1.13 Quest Diagnostics
6.1.14 Siemens Healthineers AG
6.1.15 Thermo Fisher Scientific
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Endocrine Testing Market market is studied from 2018 - 2026.
What is the growth rate of Global Endocrine Testing Market?
The Global Endocrine Testing Market is growing at a CAGR of 6.15% over the next 5 years.
What is Global Endocrine Testing Market size in 2018?
The Global Endocrine Testing Market is valued at 9170 Million USD in 2018.
What is Global Endocrine Testing Market size in 2026?
The Global Endocrine Testing Market is valued at 13119 Million USD in 2026.
Which region has highest growth rate in Global Endocrine Testing Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Endocrine Testing Market?
North America holds highest share in 2020.
Who are the key players in Global Endocrine Testing Market?
Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMérieux SA, F. Hoffmann-La Roche Ltd, Siemens AG are the major companies operating in Global Endocrine Testing Market.